Drugs /

tamibarotene

Back to Drugs List

Overview

NCI Definition [1]:
An orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity. As a specific retinoic acid receptor (RAR) alpha/beta agonist, tamibarotene is approximately ten times more potent than ATRA in inducing cell differentiation and apoptosis in HL-60 (human promyelocytic leukemia) cell lines in vitro. Due to a lower affinity for cellular retinoic acid binding protein (CRABP), tamibarotene may show sustained plasma levels compared to ATRA. In addition, this agent may exhibit a lower toxicity profile than ATRA, in part, due to the lack of affinity for the RAR-gamma receptor, the major retinoic acid receptor in the dermal epithelium.

Clinical Trials

View Clinical Trials for tamibarotene

Tamibarotene has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating tamibarotene, 1 is phase 2 (1 open) and 1 is phase 3 (1 open).

Complex karyotype, Loss of Y, and Monosomy 7 are the most frequent biomarker inclusion criteria for tamibarotene clinical trials.

Myelodysplastic syndromes is the most common disease being investigated in tamibarotene clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Tamibarotene
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating tamibarotene and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
am-80, tos-80t, 4 [(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl) carbamoyl]benzoic acid, tm-411, 4-((5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl), am80, tamibarotene, amnolake, 4-((5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl)benzoic acid, inno-507, am 80, z-208, tamibaro, tamibarotene, retinobenzoic acid, benzoic acid, 4-(((5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino)carbonyl)-, am-80, sy-1425, retinobenzoic acid, benzoic acid, 4-(((5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)amino)carbonyl)-, amnoid, n-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)terephthalamic acid
NCIT ID [1]:
C71025

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.